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Radioprotective effects of amifostine and melatonin as well as their ability to modulate the level of 
spontaneous and -irradiation-induced genetic changes on human peripheral blood lymphocytes were 
investigated using the cytokinesis-block micronucleus (CBMN) assay and sister chromatid exchange (SCE). 
Parallel blood samples were pre-treated with amifostine, melatonin and their combination for 30 minutes. 
Negative controls were also included. After the treatment with radioprotectors, one blood sample of each 
experimental group was exposed to -rays from a 60Co source. The radiation dose absorbed was 2 Gy. Our 
research confirmed the radioprotective effects of both chemicals in vitro, with no significant genotoxicity. 
Pre-treated irradiated blood samples showed a decrease in the total number of micronuclei (MN) and 
in the number of cells with more than one MN. They also showed significantly lower mean SCE values. 
This study shows that it is possible combine these radioprotectors by adjusting the doses of amifostine to 
achieve the best radioprotective effect with as few side effects as possible. However, further in vitro and 
clinical studies are needed to clarify their mechanisms of action and possible interactions.
KEY WORDS: ionising radiation, peripheral blood, radioprotectors
Recent technological advancement has made 
it possible to produce high therapeutical doses of 
radiation and/or chemotherapy which have increased 
the chances to cure a patient or prolong the emission 
of a number of neoplasms (1).
Ionising radiation causes a variety of changes 
in the living cell, which depend on the absorbed 
dose, duration of exposure, interval of exposure, 
and susceptibility of the tissue. Ionising radiation 
forms radicals in the DNA (direct effect) and in the 
surrounding water molecules of the hydration shell 
of the DNA (indirect effect), which in turn destroy 
DNA (2). 
The use of ionising radiation in cancer therapy 
may lead to transient and/or permanent injury 
to normal tissues within the treatment field. The 
magnitude of damage depends both on the volume 
of tissue irradiated and the dose of radiation delivered 
(3). To increase the therapeutic index of radiation 
therapy, various modes of radioprotection have been 
developed that selectively reduce cytotoxic effects to 
normal tissues (4).
Because radiation-induced cellular damage is 
attributed primarily to the harmful effects of free 
radicals, molecules with radical scavenging properties 
are particularly promising as radioprotectors (5, 6). 
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However, most of them produce serious side effects, 
and some are considered to be toxic at the doses 
required for radioprotection (7). 
The most effective compound studied for its 
radioprotective efficacy is amifostine or S-2-(3-
amino-propylamino) ethylphosphorothioic acid 
(synonyms: WR-2721, ethyol). According to preclinical 
studies, amifostine protects normal tissues from 
the cytotoxic effects of radiotherapy. It is a pro-drug 
that is dephosphorylated in the tissue by alkaline 
phosphatase to a free thiol, the active metabolite WR-
1065 (8-10). The protection of cell damage by WR-
1065 is thought to occur through scavenging oxygen-
derived free radicals (induced by ionising radiation 
and certain types of chemotherapy) and hydrogen 
donation to repair damaged target molecules (11). 
Although amifostine is the best-known radioprotector 
and cytoprotector that has been incorporated into 
general oncology practice, it still has a number of 
undesirable side effects, severe enough to limit the 
amount of the drug tolerated (12, 13). Moreover, the 
data regarding its action at the cellular level remain 
unclear (4).
In the last decade there have been reports 
on the radioprotective ability of melatonin, an 
endogenous compound mainly synthesised by the 
pineal gland in the human brain. Melatonin (N-
acetyl-5-methoxytryptamine) is a ubiquitously acting 
molecule with several functions. It is highly lypophilic 
and somewhat water-soluble as well. The widespread 
cellular distribution of melatonin may allow it to interact 
with all molecules, thereby reducing oxidative damage 
to molecules both in lipid and aqueous environments 
of the cell. It was reported that melatonin directly 
scavenges the highly toxic hydroxyl radicals both in
vitro and in vivo, as well as several other reactive 
species such as singlet oxygen, peroxynitrite anion (5, 
6). Its free radical–scavenging capacity is mediated 
by electron donation (14). Results of different studies 
indicate that both the acute and chronic toxicity of 
melatonin is extremely low (5, 6). 
This study investigated the effects of amifostine 
and melatonin on the extent of spontaneous as well as 
radiation-induced DNA damage in human peripheral 
lymphocytes irradiated with -rays in vitro. DNA 
damage was estimated using two well-established 
biomarkers (15): the cytokinesis-block micronucleus 
assay (CBMN) and the sister chromatid exchange 
(SCE) analysis. In addition to the assessment of 
DNA and chromosome damage, we also analysed 
lymphocyte proliferation in vitro.
MATERIAL AND METHODS
The study was performed on peripheral blood 
(V=40 mL) obtained from a healthy non-smoking 
male donor (aged 25 years) by venipuncture into 
heparinised tubes (Becton Dickinson, USA). 
Parallel samples (V=5 mL) were pre-treated for 
30 minutes with amifostine (7.7 mmol L-1, Sigma), 
melatonin (2 mmol L-1, Sigma) and their combination. 
Negative controls (untreated samples) were also 
included. After the treatment with radioprotectors, 
one blood sample from each experimental group 
was exposed to -rays from a 60Co source (Alcyon, 
CGR-MeV) at room temperature. For this purpose, 
vacutainer containing blood sample was mounted 
on an acrylic phantom (dimensions: 20 cm x 20 
cm x 15 cm) at the depth of 5.5 cm and was placed 
transversally to the axis of irradiation. The radiation 
field was 15 cm x 15 cm, and the distance between 
the surface of the phantom and the source of 
radiation was 80 cm. Total exposure to radiation 
lasted 1.24 min and the absorbed dose was 2 Gy. 
Other radioprotector-treated blood samples were 
not irradiated, but they were handled in the same 
manner. Amifostine and melatonin were used in their 
therapeutic concentrations. The radiation dose of 2 Gy 
was chosen because it is the standard fraction applied 
daily in fractionation regimens in radiotherapy.
Lymphocyte cultures for the CBMN assay and 
the SCE analysis were established from each blood 
sample.
CBMN assay was performed using a standard 
protocol, as described by Fenech and Morley (16).
The frequency of MN induction was evaluated by 
scoring 1000 binucleated lymphocytes per sample. 
Slides were analysed blind at 1000x magnification. 
Cell were scored according to the criteria outlined 
by Fenech et al. (17). The data are expressed as the 
number of MN per 1000 binucleated cells as well as the 
frequency of binucleated cells containing one or more 
MN. To provide data regarding proliferation kinetics, 
the frequencies of mono-, bi-, tri- and tetranucleate 
cells per each treatment group were determined. A 
nuclear division index (NDI) was calculated according 
to the formula proposed by Eastmond and Tucker
(18) as follows: NDI=(1xM1+2xM2+3xM3+4xM4)/N,
where M1 to M4 represent the number of cells with 
one to four nuclei and N is the total number of cells 
scored. In our study N was 1000 cells. The statistical 
significance of the differences between the observed 
Kopjar N, et al. IN VITRO STUDY OF RADIOPROTECTORS
Arh Hig Rada Toksikol 2006;57:155-163
157
MN frequencies was tested using the 2-test. The level 
of statistical significance was set at p<0.05.
The SCE analysis was performed according to the 
standard protocol (19). A total of 100 well-spread, 
second-division metaphases (50 per replicate) were 
examined to determine the SCE frequency per sample. 
Every point of exchange was counted as an SCE. 
Exchanges at the centromere were included only when 
twisting at this point could be ruled out. The results of 
SCE were expressed as mean±SD for each analysed 
sample. The data were analysed using the Statistica 
5.0 (StatSoft) package. Multiple comparisons between 
groups were done by means of ANOVA with the 
Scheffé post-hoc test and considered significantly 
different when p values were less than 0.05.
In addition to SCE examination, the BrdU 
differential staining technique was used to assess the 
effects of ionising radiation and radioprotectors on 
cell replication. For each sample the proportion of 
the first (M1), second (M2) and third (M3) metaphases 
was determined in 100 consecutive metaphases. 
The proliferation rate index (PRI) was calculated as 
follows: PRI=(1M1+2M2+3M3)/100 (20). Statistical 
significance of data obtained for cellular kinetics was 
tested using the 2-test.
RESULTS
CBMN assay
The background level of MN in blood donor was 7 
MN per 1000 binucleated cells (Table 1). Amifostine 
in the concentration of 7.7 mmol L-1 and melatonin 
in the concentration of 2 mmol L-1 induced a similar 
number of MN in non-irradiated blood samples. 
Although slightly elevated with respect to the control 
sample, the difference in MN was not statistically 
significant. Moreover, combined application of both 
radioprotectors in the non-irradiated blood sample 
did not cause any measurable changes (Table 1). 
These results suggest that both chemicals in tested 
concentrations did not induce significant damage to 
lymphocyte genome in vitro.
Table 1 shows that -irradiation (2 Gy) increased 
the number of MN in exposed lymphocytes over 12-
fold (89 MN per 1000 binucleated cells). In blood 
samples irradiated in the presence of single amifostine 
and melatonin, as well as their combination, protective 
effects were observed. Both compounds caused a 
clear reduction in frequency of radiation-induced 
MN. Moreover, the proportions of cells containing 
more than one MN were also significantly decreased 
(Table 1). According to our observations, single 
melatonin offers better protective effects to -irradiated 
human lymphocytes in vitro than single amifostine. 
However, the best radioprotective effects in vitro were 
observed when the combination of both substances 
was added to blood samples prior to irradiation. 
Differences between the total number of MN 
recorded after treatments with single melatonin and 
combination of amifostine and melatonin in irradiated 
samples were not statistically significant (Table 1). 
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Table 1  Results of the micronucleus assay of blood samples irradiated with gamma-rays (2 Gy) after in vitro pre-treatment with radioprotectors
amifostine (7.7 mmol L-1), melatonin (2 mmol L-1), and their combination. Non-irradiated samples treated with the same radioprotectors 
were studied simultaneously, and corresponding negative controls were also included.




without MN with MN 1 MN 2 MN 3 MN M1 M2 M3 M4
IRRADIATED SAMPLES (absorbed dose = 2 Gy)
Amifostine 959 41* 33 6 2 51* 109 719 86 86 2.15
Melatonin 967 33* 31 2 - 35* 112 746 75 67 2.10
A + M 970 30* 26 4 - 34* 124 755 64 57 2.07
Control 927 73*, 57 16 - 89*, 120 759 59 62 2.06
NON-IRRADIATED SAMPLES
Amifostine 987 13 13 - - 13 57 804 64 75 2.16
Melatonin 988 12 10 1 - 12 92 748 79 81 2.15
A + M 993 7 7 - - 7 148 715 54 83 2.07
Control 993 7 7 - - 7 105 752 63 80 2.12
MN - micronucleus; M1 to M4 represents the number of lymphocytes with one to four nuclei; NDI (Nuclear Division Index); NDI= (1M1+2M2+3M3+4M4)/1000 
cells counted in total. * - significantly increased compared to non-irradiated sample pre-treated with the same radioprotector;  - significantly increased 
compared to other irradiated samples (p<0.05; 2 – test).
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NDI was calculated to assess the effects of 
radioprotectors on the proliferative capacity of 
irradiated human lymphocytes. The values of NDI in 
negative controls pre-treated with single amifostine or 
melatonin were slightly higher than in control sample, 
suggesting enhanced proliferation of lymphocytes. 
However, it was observed that -radiation at a dose of 
2 Gy caused a delay in cell proliferation, as manifested 
by a change in relative numbers of M1 to M4 cells. 
Our results indicate that radioprotectors modulate 
the proliferative activity, especially when added in 
combination. The same value of NDI in -irradiated
and non-irradiated lymphocytes pre-treated with 
amifostine and melatonin may reflect a successful 
overcome of cytotoxic effects caused by ionising 
radiation (Table 1). 
SCE analysis
In this study we also wanted to see whether 
radioprotectors, alone or in combination, induced any 
changes in the incidence of SCE in non-irradiated and 
-irradiated human lymphocytes in vitro. The results 
of SCE analysis are shown in Table 2 and Figure 1.
The background level of SCE in 100 metaphases 
was 4.01±1.40 in a range of 1 SCE to 8 SCE per cell 
(Table 2). Our results demonstrate that the tested doses 
of amifostine and melatonin do not induce genotoxic 
response in non-irradiated human lymphocytes 
in vitro. Namely, the frequencies of SCE in blood 
samples pre-treated with amifostine or melatonin 
alone did not differ significantly from SCE frequences 
recorded in the control sample. We also observed that 
the combination of both radioprotectors led to a drop 
in SCE frequency (3.73±1.54; range 1 SCE to 7 SCE 
per cell) with respect to samles pretreated with either 
radioprotector alone and to negative control. However, 
this difference was statistically significant only with 
the sample pre-treated with melatonin. These results 
indicate that the combination of both radioprotectors 
reduced the amounts of free radicals and even 
diminished the baseline DNA damage present at the 
moment of blood sampling.
As reported in Table 2, -irradiation (2 Gy) caused 
a significant increase in SCE frequency (6.97±2.24) 
and range (3 SCE to 16 SCE per cell) in the exposed 
lymphocytes compared to non-irradiated negative 
control. The addition of either radioprotector alone 
or in combination before -irradiation significantly 
reduced SCE frequency. According to our results, the 
best radioprotective effects on -irradiated lymphocytes 
in vitro were observed in the sample pre-treated with 
the combination of both chemicals. However, the 
differences between mean SCE frequencies obtained 
for single radioprotectors and their combination were 
not statistically significant (Table 2). Figure 1 shows 
the distribution of SCE in all analysed samples, 
confirming the above observations.
The results of the cell-cycle analysis show that 
-irradiation slowed down the lymphocyte cell cycle 
in vitro, while both radioprotectors altered this effect 
to some extent. The delay in cell turnover times was 
Table 2  Frequency of sister chromatid exchanges (SCE) and cell cycle kinetics in human peripheral blood lymphocytes irradiated with gamma-
radiation after pre-treatment with amifostine, melatonin, and their combination in vitro. Non-irradiated samples treated with the same 
radioprotectors were studied simultaneously, and corresponding negative controls were also included.
SCE in 100 cells
(mean±SD) SCE range
Number of cells in
PRI
M1 M2 M3
IRRADIATED SAMPLES (absorbed dose = 2 Gy)
Amifostine 5.00±1.65 2-9 23 60 17 1.94
Melatonin 5.16±1.45 3-8 22 67 11 1.89
A + M 4.72±1.73 1-9 25 58 17 1.92
Control 6.97±2.24 3-16 28 52 20 1.92
NON-IRRADIATED SAMPLES
Amifostine 4.05±1.34 1-8 22 62 16 1.94
Melatonin 4.42±1.72 1-9 19 59 22 2.03
A + M 3.73±1.54* 1-7 17 65 18 2.01
Control 4.01±1.40 1-8 15 64 21 2.06
SCE frequency was scored in 100 cells per sample. Proliferation Rate Index, (PRI) was determined using the formula PRI = (1M1 +2M2. + 3M3)/100
where M1, M2, and M3 corresponded to the number of cells in first, second and third in vitro mitotic division. - significantly increased with respect 
to other irradiated samples. *- significantly decreased compared to non-irradiated sample pre-treated with melatonin; (p<0.05; ANOVA, post-hoc 
Scheffé test).
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manifested as a change in the relative frequencies 
of M1, M2 and M3 metaphases (Table 2). Amifostine 
given alone before irradiation slightly enhanced the 
proliferation of lymphocytes, whereas melatonin 
slowed it down, but not significantly. In combination, 
the two radioprotectors did not significantly affect 
the proliferation of treated lymphocytes compared to 
control. As shown in Table 2, their effects on the cell 
cycle did not significantly differ either between them 
or with respect to the control. Amifostine induced 
a slight, but statistically not significant delay in the 
first and second division in vitro, compared to other 
samples analysed (Table 2).
DISCUSSION
There is a continued interest and need to identify 
and develop non-toxic radioprotective compounds. 
An efficient radioprotector could prove useful in 
occupational and therapeutic settings where ionising 
radiation is used or where exposure occurs; after 
nuclear accidents which leave radioactivity in the 
environment; and during space travel to protect 
astronauts from the effects of high doses of radiation 
associated with solar flares (21).
This study focused on two compounds, amifostine 
and melatonin, and their ability to modify the level 
of spontaneous and -irradiation-induced genetic 
changes on human peripheral blood lymphocytes. 
The main result of our research was the confirmation 
of the radioprotective effects of both chemicals in
vitro, with no significant genotoxicity, as revealed 
using two well-established and sensitive biomarkers: 
the CBMN assay and the SCE analysis.
Our goal was also to evaluate the cytogenetic 
effects of single exposure to -radiation of 2 Gy, 
because it is a standard fraction applied daily to cancer 
patients in fractionation regimens in radiotherapy. This 
study confirmed the ability of -radiation to increase 
the incidence of MN in exposed human lymphocytes, 
as reported previously in many other in vitro and in
vivo investigations (22-26).
Reports on SCE induction after exposure to 
ionising radiation in vivo and in vitro are contradictory. 
Although ionising radiation is known to damage DNA, 
it was observed early on that it is a poor inducer of 
SCEs. The extent of stimulation of SCE by in vitro
irradiation varies from no increase to levels as high 
as two to three times higher than the baseline level 
(27). Our results are in good agreement with these 
observations: single in vitro exposure of human 
lymphocytes to -irradiation of 2 Gy in our study 
nearly doubled the mean SCE frequency measured 
in the non-irradiated sample. Our result (6.97±2.24) 
is even lower than the level recorded in previous 
study by Iijima and Morimoto (28) (8.6±0.6), who 
also exposed human lymphocytes to the same 
dose of -rays. These data suggest that -irradiation
does not induce long-lived lesions in the DNA of 
G0 lymphocytes that can be expressed as SCE in 
subsequent mitoses.
We noticed that -irradiation caused delays in 
different phases of the cell cycle. These observations 
are consistent with earlier reports (28, 29). In general, 
different forms of ionising radiation delay lymphocyte 
cell cycle. Purrot et al. (30) have estimated that after 
exposure to radiation, lymphocytes suffer an average 
mitotic delay of about 1 h per gray. The data from 
previous studies indicate that mutagens that cause 
larger inductions of SCE also induce long cell-cycle 
delays (31) as well as that higher PRI correlates with 
lower SCE frequency (20). These delays in cell cycle 
allow the cell to repair DNA and try to reduce the 
adverse effects of radiation (32). Our results confirm 
these observations.
To our knowledge, there have been no published 
studies investigating possible synergistic radioprotective 
effects of amifostine and melatonin using cytogenetic 
biomarkers. While the cytogenetic effects of melatonin 
were studied previously, the reports on amfiostine 
effects on the cellular level are limited. Melatonin was 
found to be an efficient radioprotector when studied on 
animal and human models in vitro and in vivo. Badr et 
al. (14) observed that MN frequency in polychromatic 
erythrocytes and the number of chromosomal 
Figure 1 Distribution of mean SCE in blood samples pre-treated with 
amifostine (A), melatonin (M), and their combination (A+M). 
(*) Irradiated samples; (C) negative controls.
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aberrations in spermatogonia and spermatocytes 
were significantly reduced in melatonin-pre-treated 
irradiated mice compared to those treated with diluent 
only. Vijayalaxmi et al. (33-35) reported a significant 
decrease in genetic damage, as well as lower MN 
frequency in human blood lymphocytes pre-treated 
with melatonin and exposed to 1.5 Gy -radiation.
Moreover, their results suggest that melatonin at 
the dose levels 0.05 mmol L-1 to 1.0 mmol L-1 did 
not significantly increase SCE frequency (35). In our 
study, we used a higher concentration of melatonin 
(2 mmol L-1) and a higher radiation dose (2 Gy) than 
reported in previous in vitro studies. Even so, it 
confirmed the significant radioprotective effects and 
no genotoxicity of melatonin. Moreover, our results 
for SCE (mean SCE:4.42±1.72) are very similar to 
those obtained by Awara et al. (36) (mean SCE: 
4.90±0.37), who investigated possible anti-mutagenic 
effects of melatonin on carbamazepine-treated human 
peripheral lymphocytes.
Even though many other substances with assumed 
cytoprotective effects are the subjects of laboratory 
and/or clinical studies, at the moment there is no 
ideal protective strategy to be universally employed 
in patients receiving radio- or chemotherapy. Many 
recent clinical studies have shown that amifostine is 
a useful radioprotector (4, 5, 9-13). However, no data 
regarding its possible genotoxic effects are available. 
The results of our study in vitro indicate that exposure 
to a single dose of amifostine is not associated 
with significant genotoxicity in human peripheral 
lymphocytes. No statistically significant increase in 
the frequency of SCE and MN were found in treated 
samples as compared with control. Furthermore, our 
results showed noteworthy radioprotective effects of 
amifostine when applied prior to -irradiation. Similar 
results were reported by Littlefield and Hoffman
(37), who observed that amifostine metabolite WR-
1065 caused a significant decrease in chromosome 
aberrations and micronuclei in G0 human lymphocytes 
irradiated with X-rays and neutrons.
Although amifostine was tolerated well in many 
clinical trials, it is expensive, its use is limited to clinical 
settings because it must be given intravenously, 
and it has various undesirable side effects (nausea, 
vomiting, flushes, mild somnolence, hypocalcaemia 
and hypotension) (10, 21).
We believe that combined use of amifostine 
and melatonin (or other radioprotectors) would in 
some circumstances prove beneficial and might 
overcome a part of undesired side effects produced 
by amifostine alone. The results of our study, where 
amifostine and melatonin were added simultaneously 
to blood samples prior to the -irradiation, indicate 
that both compounds act synergistically to reduce 
DNA damage. Therefore, in some conditions, it would 
be reasonable to administer them in combination, 
exploiting their best radioprotective properties, since 
each acts as very specific antioxidant. An important 
advantage of amifostine over melatonin is its 
differential and selective uptake only in normal, but 
not in tumor cells (4, 12). In contrast, melatonin, as 
amphiphilic molecule, can enter any cell type and 
even cell compartment (38). The combination of 
these substances could also be beneficial because 
amifostine itself does not reduce anti-tumor activity of 
other drugs (10); whereas some studies indicate that 
melatonin itself has an antitumour effect, as it slows 
down the cell cycle (39). Another feature that possibly 
increases the efficiency of melatonin in reducing 
oxidative stress is that the second and third generation 
of its metabolites seem to be efficient scavengers (40). 
Moreover, melatonin may also influence DNA repair 
enzymes directly and indirectly stimulate intracellular 
signals to activate genes responsible for protein 
synthesis in DNA repair (5).
In conclusion, the data obtained in our study 
suggest that amifostine and melatonin prevent DNA 
damage inflicted by -radiation in human peripheral 
blood lymphocytes in vitro, if given before exposure. 
They also suggest that amifostine doses should be 
adjusted for optimal radioprotective effect in healthy 
cells, with as few side effects in cancer patients 
as possible. Despite its limitations, this study has 
produced new data that contribute to the growing 
body of evidence that both amifostine and melatonin 
are effective radioprotectors. However, before they are 
approved for clinical use, further experimental studies 
using different cytogenetic and molecular biomarkers 
at the same time and well designed clinical studies 
are needed to clarify the exact mechanisms of their 
radioprotective action and possible interactions.
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Sažetak
RADIOPROTEKTIVNI UÈINCI AMIFOSTINA I MELATONINA NA LJUDSKE LIMFOCITE 
IZLOŽENE -ZRAÈENJU U UVJETIMA IN VITRO
Primjena zraèenja u lijeèenju zloæudnih bolesti (radioterapija) znaèajno pridonosi preživljenju bolesnika, ali 
izaziva i niz neželjenih uèinaka na zdrave stanice i tkiva. Nuspojave ionizirajuæeg zraèenja mogu se znaèajno 
smanjiti s pomoæu kemijskih spojeva s antioksidativnim uèinkom koji djeluju kao ‘hvataèi’ slobodnih radikala i 
štite vrlo osjetljivu molekulu DNA. Meðu spojeve s pretpostavljenim ili dokazanim radioprotektivnim uèincima 
ubrajaju se amifostin i melatonin, koji su predmet istraživanja ovog rada. U literaturi nema dovoljno podataka 
o njihovoj genotoksiènosti ni meðusobnim interakcijama. Stoga smo primjenom mikronukleusnog testa i 
analize izmjena sestrinskih kromatida (SCE) u uvjetima in vitro istražili djelovanje amifostina i melatonina 
na genom neozraèenih i ozraèenih ljudskih limfocita periferne krvi. Pojedinaèno ili u kombinaciji, amifostin i 
melatonin dodavani su u uzorke pune krvi 30 minuta prije jednokratnog ozraèivanja -zrakama izvora 60Co.
Doza zraèenja iznosila je 2 Gy, a koncentracije radioprotektora odgovaraju onima prije upotrebljavanim 
u klinièkoj primjeni ili u preliminarnim istraživanjima na ljudskoj populaciji. Ozraèena krv kultivirana je 72 
h u uvjetima in vitro prema standardnim protokolima za mikronukleusni test i test izmjena sestrinskih 
kromatida. Uèinci amifostina i melatonina usporedo su istraživani i na kontrolnim, neozraèenim uzorcima 
krvi. Dobiveni rezultati upuæuju na znaèajno smanjenje ukupnog broja mikronukleusa i smanjenje udjela 
stanica s više od jednog mikronukleusa te sniženje ukupnog broja i raspona izmjena sestrinskih kromatida 
u pretretiranim uzorcima krvi. Potvrðen je vrlo dobar radioprotektivni uèinak svakog spoja testiranog 
posebno, a ujedno je utvrðeno da oba spoja sinergistièki djeluju na snižavanje razina ošteæenja izazvanih 
u genomu limfocita pod utjecajem -zraka. S obzirom na to da primjenom citogenetièkih testova nije 
dokazana genotoksiènost navedenih radioprotektora za ljudske limfocite u uvjetima in vitro, dobiveni 
rezultati govore u prilog daljnjih istraživanja ovih spojeva i njima srodnih tvari u uvjetima in vivo te njihove 
moguæe zajednièke primjene u klinièkoj praksi.
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